설명

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 10억 동안 2021-2027, 연평균 성장률로 성장 (CAGR) ~의 8.6% 예측 기간 동안, 데이터 및 분석 회사 StrategyHelix에 따르면. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

이 보고서는 기간 동안 최신 시장 규모 데이터를 제공합니다. 2017-2020 그리고 예측 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, 기술, age, analysis target, 및 지역. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. 기술별, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, 다른 사람. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI 그룹, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, 퍼킨엘머 주식회사, Quest Diagnostics 통합.

이 보고서는 이 업계에서 활동하는 회사 및 조직에 매우 귀중한 리소스입니다.. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, 정책 입안자, 학생, 및 분석가.

보고 범위

Disease: 심혈관, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
기술: polymerase chain reaction (PCR), next-generation sequencing, microarrays, 다른 사람
Age: children, and adult
지역: 북아메리카, 아시아 태평양, 유럽, 및 기타 국가 (열)
Analysis target: multiple genes, whole exome, single genes, and whole genome
고려한 연도: 이 보고서는 기간을 다룹니다 2017 에게 2027

이해관계자를 위한 주요 이점

Get a comprehensive picture of the global rare disease diagnostics market
현지 데이터 및 분석을 기반으로 지역 전략 및 전략적 우선순위 파악
성장 분야 및 투자 동향 파악
Understand what the future of the global rare disease diagnostics market looks like
경쟁 구도 및 기회의 창 식별

목차

1. 시장 정의
2. 연구 방법론
3. 시장 데이터 & 시야
3.1 시장 가치
3.2 시장 가치 예측
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 폴리 메라 제 연쇠 반응 (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 기타
6. Rare Disease Diagnostics Market by Age
6.1 어린이들
6.2 성인
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 북아메리카
8.2 아시아 태평양
8.3 유럽
8.4 나머지 세계 (열)
9. 회사 프로필
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI 그룹
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 퍼킨엘머, 주식회사.
9.10 Quest Diagnostics 통합
10. 부록
10.1 스트래티지헬릭스 소개
10.2 부인 성명